Stock 4886 ASKA PHARMACEUTICAL HOLDINGS CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ASKA Pharmaceutical Holdings Co.,Ltd.

Equities

4886

JP3119660003

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-12 am EDT 		5-day change 1st Jan Change
2,421 JPY +0.88% Intraday chart for ASKA Pharmaceutical Holdings Co.,Ltd. +0.08% +35.71%
2023 Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
2023 ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 31,095 44,958 35,672 33,620 62,863 68,585 - -
Enterprise Value (EV) 1 40,220 50,839 32,615 28,338 55,110 56,277 51,395 46,227
P/E ratio 47.8 x 15.4 x 8.35 x 7.92 x 8.33 x 13.1 x 13.1 x 11.1 x
Yield 1.55% 0.95% 1.19% 1.35% 1.8% 2.07% 2.11% 2.38%
Capitalization / Revenue 0.59 x 0.81 x 0.63 x 0.56 x 1 x 1.07 x 1.01 x 0.98 x
EV / Revenue 0.77 x 0.92 x 0.58 x 0.47 x 0.88 x 0.88 x 0.76 x 0.66 x
EV / EBITDA 7.63 x 7.35 x 2.39 x 3.44 x 6.02 x 5.92 x 5.33 x 4.16 x
EV / FCF -15.8 x 9.35 x 14.9 x 13.7 x 17.3 x 12.1 x 13.1 x 8.76 x
FCF Yield -6.34% 10.7% 6.7% 7.32% 5.79% 8.29% 7.65% 11.4%
Price to Book 0.75 x 0.94 x 0.73 x 0.62 x 1.02 x 1.04 x 0.98 x 0.92 x
Nbr of stocks (in thousands) 28,320 30,563 28,243 28,276 28,329 28,329 - -
Reference price 2 1,098 1,471 1,263 1,189 2,219 2,421 2,421 2,421
Announcement Date 5/12/20 5/11/21 5/12/22 5/11/23 5/10/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 52,542 55,181 56,607 60,461 62,843 64,019 67,794 69,782
EBITDA 1 5,268 6,915 13,633 8,235 9,162 9,500 9,642 11,100
EBIT 1 1,507 3,609 4,795 5,108 6,500 6,844 6,772 7,950
Operating Margin 2.87% 6.54% 8.47% 8.45% 10.34% 10.69% 9.99% 11.39%
Earnings before Tax (EBT) 1 901 3,575 6,163 5,357 9,862 6,855 7,290 7,961
Net income 1 649 2,713 4,290 4,238 7,545 5,242 5,235 6,152
Net margin 1.24% 4.92% 7.58% 7.01% 12.01% 8.19% 7.72% 8.82%
EPS 2 22.96 95.72 151.2 150.1 266.5 185.0 184.9 217.2
Free Cash Flow 1 -2,550 5,437 2,185 2,075 3,192 4,665 3,930 5,277
FCF margin -4.85% 9.85% 3.86% 3.43% 5.08% 7.29% 5.8% 7.56%
FCF Conversion (EBITDA) - 78.63% 16.03% 25.2% 34.84% 49.11% 40.76% 47.54%
FCF Conversion (Net income) - 200.41% 50.93% 48.96% 42.31% 88.98% 75.08% 85.78%
Dividend per Share 2 17.00 14.00 15.00 16.00 40.00 50.00 51.00 57.50
Announcement Date 5/12/20 5/11/21 5/12/22 5/11/23 5/10/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 S1 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4
Net sales 1 27,403 28,477 15,702 12,428 15,269 14,903 30,172 17,087 13,202 16,023 15,625 31,648 17,176 14,019 16,420 16,030 32,450 17,540 14,510
EBITDA - - - - - - - - - - - - - - - - - - -
EBIT 1 1,946 2,657 2,020 118 1,664 1,215 2,879 2,162 67 1,704 1,351 3,055 2,471 974 1,970 1,500 3,470 2,690 840
Operating Margin 7.1% 9.33% 12.86% 0.95% 10.9% 8.15% 9.54% 12.65% 0.51% 10.63% 8.65% 9.65% 14.39% 6.95% 12% 9.36% 10.69% 15.34% 5.79%
Earnings before Tax (EBT) 1,952 -4,139 9,988 - 1,805 1,214 3,019 2,348 - 1,873 - 5,410 3,110 - - - - - -
Net income 1 1,552 -2,796 6,878 208 1,323 1,023 2,346 1,837 55 1,428 2,701 4,129 2,329 1,087 1,497 1,140 2,637 2,044 668
Net margin 5.66% -9.82% 43.8% 1.67% 8.66% 6.86% 7.78% 10.75% 0.42% 8.91% 17.29% 13.05% 13.56% 7.75% 9.12% 7.11% 8.13% 11.65% 4.6%
EPS 54.77 -98.52 242.3 - 46.94 - 83.18 65.01 - 50.51 - 145.9 82.20 - - - - - -
Dividend per Share 7.000 7.000 - - - - 8.000 - - - - 20.00 - - - - - - -
Announcement Date 11/4/20 11/1/21 2/7/22 5/12/22 8/8/22 11/7/22 11/7/22 2/6/23 5/11/23 8/7/23 11/6/23 11/6/23 2/5/24 5/10/24 - - - - -
1JPY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 9,125 5,881 - - - - - -
Net Cash position 1 - - 3,057 5,282 7,753 12,308 17,190 22,358
Leverage (Debt/EBITDA) 1.732 x 0.8505 x - - - - - -
Free Cash Flow 1 -2,550 5,437 2,185 2,075 3,192 4,665 3,931 5,277
ROE (net income / shareholders' equity) 1.5% 6.3% 8.8% 8.2% 13% 8.2% 8.3% 8.5%
ROA (Net income/ Total Assets) 2.11% 2.77% 5.17% 6.14% 7.33% 7.35% 8% 8.4%
Assets 1 30,734 97,942 82,940 69,028 102,892 71,327 65,442 73,232
Book Value Per Share 2 1,468 1,569 1,735 1,928 2,186 2,321 2,465 2,625
Cash Flow per Share 2 156.0 212.0 253.0 261.0 361.0 261.0 299.0 310.0
Capex 1 2,058 1,104 657 1,276 1,320 1,660 2,160 1,910
Capex / Sales 3.92% 2% 1.16% 2.11% 2.1% 2.59% 3.19% 2.74%
Announcement Date 5/12/20 5/11/21 5/12/22 5/11/23 5/10/24 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ASKA Pharmaceutical Holdings Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2,421 JPY
Average target price
2,450 JPY
Spread / Average Target
+1.20%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ASKA PHARMACEUTICAL HOLDINGS CO.,LTD. Stock ASKA Pharmaceutical Holdings Co.,Ltd.
+35.71% 434M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4886 Stock
  4. Financials ASKA Pharmaceutical Holdings Co.,Ltd.